Late-Life Depression: Focus on Inflammation

View at publisher Summarise with VIRAT
Authors: Scott R. Beach
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Late-life depression often features "depression equivalents" like somatic symptoms rather than sadness, complicating diagnosis. Inflammation may impair dopamine and serotonin function, potentially explaining reduced antidepressant efficacy in this subtype. CRP greater than 3 appears most associated with inflammatory depression, though routine screening is not yet recommended. Current evidence is too heterogeneous to support concrete recommendations for anti-inflammatory agents in late-life depression. Dopaminergic agents, kappa opioid receptor antagonists, behavioral activation, and neuromodulation targeting reward circuits may offer alternatives.

Fields of Study & Subjects

Tryptophan and brain disorders Treatment of Major Depression Stress Responses and Cortisol

Publication details

Publication date
26 March 2026
Language
EN